Kolitis Pseudomembranosa

01Pathophysiology

Pseudomembranous colitis is a toxin-mediated inflammatory disease of the colon caused by Clostridioides difficile, a gram-positive, anaerobic, spore-forming bacillus. Understanding the spore-forming nature is central to grasping both the pathogenesis and the epidemiology, because spores survive on environmental surfaces, are resistant to alcohol-based hand sanitizers, and are transmitted via the fecal-oral route in healthcare settings.

The disease begins when the normal colonic microbiome is disrupted, most commonly by broad-spectrum antibiotics. This disruption creates an ecological vacuum. C. difficile spores, acquired from the hospital environment or from asymptomatic carriers, germinate into vegetative forms in the colon. These vegetative cells then produce two large exotoxins: Toxin A (an enterotoxin) and Toxin B (a cytotoxin). Both toxins work by inactivating Rho GTPases in the colonic epithelial cells through glucosylation. Rho GTPases are critical regulators of the actin cytoskeleton and tight junctions. When they are inactivated, the actin cytoskeleton disassembles, tight junctions between epithelial cells break down, and the mucosal barrier loses its integrity.

This leads to a cascade: fluid leaks into the intestinal lumen (producing watery diarrhea), neutrophils infiltrate the damaged mucosa, and an intense acute inflammatory response ensues. The accumulation of fibrin, mucus, necrotic epithelial cells, and neutrophils on the surface of the inflamed mucosa forms the characteristic pseudomembranes, which are the raised, yellow-white plaques visible on colonoscopy. The term "pseudo" refers to the fact that these membranes are inflammatory exudates adherent to the mucosal surface, not true membranes.

In hypervirulent strains such as ribotype 027 (NAP1/BI), a deletion in the tcdC gene (a negative regulator of toxin production) leads to dramatically increased toxin output, binary toxin (CDT) production, and higher rates of severe disease, recurrence, and mortality.

The pathophysiology directly explains the clinical spectrum: mild toxin exposure causes watery diarrhea with minimal mucosal damage, moderate exposure causes classic pseudomembranous colitis, and severe toxin burden causes fulminant colitis with toxic megacolon, bowel perforation, and sepsis.

02Classification and Clinical Manifestation

A few critical nuances for exam purposes:

• A patient can have fulminant disease with paradoxically formed stool if an ileus is present, because the colon is not passing contents. This is a tested concept: do not assume the absence of diarrhea rules out C. difficile.

• Leukemoid reaction (WBC > 40,000 to 50,000 cells/mm${}^3^3$) in a hospitalized patient with diarrhea should immediately raise suspicion for C. difficile.

• WBC and creatinine are the two lab values that define severity. This is testable and should be memorized.

03Diagnostic Workup

The workup of suspected C. difficile infection begins with a fundamental principle: only test unformed (liquid) stool specimens in symptomatic patients. Testing formed stools or asymptomatic patients leads to false positives from carriers and is explicitly discouraged by current guidelines.

The best initial diagnostic strategy recommended by the IDSA/SHEA is a multi-step algorithm. The most commonly implemented version is a two- or three-step approach:

Step 1: Perform a combined GDH antigen + Toxin A/B EIA simultaneously using a rapid immunochromatographic assay. If both GDH and toxin are positive, the patient has confirmed C. difficile infection. If both are negative, infection is effectively ruled out.

Step 2: When results are discordant (GDH positive but toxin negative), this means the organism is present but toxin production is not confirmed by EIA. In this situation, a confirmatory NAAT/PCR for the tcdB gene is performed. If the PCR is positive, the patient is considered to have a toxigenic strain and is treated accordingly.

This two-step algorithm balances sensitivity and cost-effectiveness. GDH is an excellent screening test because of its high negative predictive value: a negative GDH result reliably excludes the diagnosis.

An alternative approach, acceptable in institutions with strict stool submission criteria (only testing truly symptomatic patients), is to use NAAT/PCR as a standalone test. However, the drawback is that PCR detects the toxin gene, not the toxin itself, meaning it can be positive in asymptomatic carriers. This is why the multi-step approach is generally preferred.

Colonoscopy is not routinely needed for diagnosis but is the procedure that reveals the classic finding of raised, yellow-white pseudomembranous plaques ranging from 2 to 10 mm scattered over the colorectal mucosa. It is typically reserved for situations where stool testing is unavailable, the clinical suspicion remains high despite negative tests, or when an alternative diagnosis must be excluded.

Repeat testing within the same diarrheal episode (within 7 days) is not recommended and should not be ordered.

04Management and Treatment

Step 0: Discontinue the Offending Antibiotic. This is the single most important initial intervention and is the "next best step" in management logic on exam questions. If the inciting antibiotic can be stopped, it should be stopped. If antibiotic therapy must continue for the primary infection, narrowing the spectrum is recommended.

Step 1: Antibiotic Treatment of CDI Itself. Per the 2021 IDSA/SHEA focused update, fidaxomicin is now the preferred first-line agent over vancomycin for both non-severe and severe initial episodes. The rationale is that fidaxomicin achieves comparable clinical cure rates to vancomycin but with significantly lower recurrence rates. Fidaxomicin is a narrow-spectrum macrolide that selectively targets C. difficile while preserving the remainder of the colonic microbiome, which is why it reduces recurrence.

• Fidaxomicin: 200 mg PO twice daily for 10 days

• Oral Vancomycin (acceptable alternative): 125 mg PO four times daily for 10 days

Metronidazole is no longer recommended as first-line treatment for initial non-severe or severe CDI. It remains reserved only as a component of fulminant disease management (administered intravenously, because oral absorption is unreliable in patients with ileus).

Step 2: Fulminant Disease Management. Patients with hypotension, shock, ileus, or toxic megacolon require aggressive combination therapy. The regimen consists of:

• Vancomycin 500 mg PO or via nasogastric tube every 6 hours (note the dose is 4 times the standard dose)

• IV metronidazole 500 mg every 8 hours (added because oral/NG medication may not reach the colon adequately in ileus)

• Rectal vancomycin (500 mg in approximately 100 mL normal saline as a retention enema every 6 hours) may be considered when ileus is present and oral/NG delivery is impaired

• Early surgical consultation is critical. Subtotal colectomy with end ileostomy is the surgical intervention when the patient continues to deteriorate despite maximal medical therapy.

Step 3: Recurrence Management. CDI recurs in roughly 20% of patients after the first episode, and recurrence risk increases substantially with each subsequent episode.

• For a first recurrence, fidaxomicin (standard 10-day or extended-pulsed regimen: 200 mg BID for 5 days, then 200 mg once daily on alternate days for 20 days) is preferred.

• Bezlotoxumab, a monoclonal antibody against Toxin B, can be administered as a single IV infusion alongside antibiotic therapy to reduce recurrence in patients at high risk (age >65, immunosuppressed, severe CDI, history of recurrence).

• For multiple recurrences (two or more), fecal microbiota transplantation (FMT) is recommended. FMT works by restoring the normal colonic microbiome, which provides colonization resistance against C. difficile. It has cure rates exceeding 85-90% for recurrent CDI.

• A vancomycin taper-and-pulse regimen is an alternative for recurrences: 125 mg QID x 10-14 days, then 125 mg BID x 7 days, then 125 mg daily x 7 days, then 125 mg every 2-3 days for 2-8 weeks.

Key Contraindication: Do not use antiperistaltic agents (loperamide, diphenoxylate) in patients with suspected or confirmed CDI, as they can precipitate toxic megacolon by reducing toxin clearance.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get questions about pseudomembranous colitis wrong is by failing to recognize the temporal relationship between antibiotic use and diarrhea onset. The vignette will describe a hospitalized patient who was recently on antibiotics (sometimes completed days or even weeks ago) and now presents with new-onset watery diarrhea. Students who focus on the current presentation without asking "what antibiotics did this patient receive?" will miss the diagnosis. The antibiotic history is the giveaway, and sometimes it is buried in the stem.

A second common trap is the treatment hierarchy. Many students default to metronidazole as the first-line treatment because older study materials still list it that way. Per the 2021 IDSA/SHEA update, metronidazole is no longer first-line. If a question asks for the best initial treatment of non-severe or severe CDI, the answer is now fidaxomicin (preferred) or oral vancomycin (acceptable). IV metronidazole is added only in fulminant disease, always in combination with high-dose vancomycin.

Another frequently tested concept is the distinction between the diagnostic tests. PCR/NAAT detects the toxin gene, not the toxin itself. This means PCR can be positive in asymptomatic carriers. The toxin EIA detects actual toxin in the stool, which correlates better with active disease. Questions may ask which test confirms active disease (toxin EIA) versus which detects the organism's genetic material (NAAT). Understanding this distinction prevents errors.

Watch for the vignette describing a patient with ileus and no diarrhea who is toxic, febrile, and has leukocytosis. The absence of diarrhea does not rule out C. difficile in the setting of ileus, and this presentation should prompt suspicion for fulminant colitis.

Finally, remember: the core competency being tested in pseudomembranous colitis questions is the ability to connect antibiotic exposure to nosocomial diarrhea, correctly sequence the diagnostic workup, and apply the updated treatment guidelines according to disease severity.